PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 10, 2025Journal of Clinical MedicineOpen Access

Geographic Variation in Persistence of Oral Anticoagulant Treatment Among Patients with Non-Valvular Atrial Fibrillation in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

BABrett D. AtwaterRSRisho SinghABAli Bonakdar

Discussion

Loading...

Member takes

Overview

Study shows significant geographic variation in persistence of oral anticoagulants among patients with non-valvular atrial fibrillation, suggesting regional prescribing trends impact treatment adherence.

Key Points

  • Persistence rates for oral anticoagulants in patients with non-valvular atrial fibrillation varied regionally in the United States.
  • At 12 months, persistence rates ranged from 40.3% to 78.8% for OAC-naïve patients, with differences observed across US regions.
  • Data analyzed included 260,001 OAC-naïve patients from various regions, highlighting significant geographical disparities in treatment persistence.
  • The findings underline the relevance of understanding geographic trends in prescribing patterns for improving real-world patient care.

Cite This Study

Atwater et al. (2025) studied this question.

synapsesocial.com/papers/68c23c66b210217d6478973ehttps://doi.org/10.3390/jcm14176265
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world adherence trajectories to direct oral anticoagulants in naive patients with atrial fibrillation in Spain2025
  2. 2Racial disparities and trends in anticoagulant use among ambulatory care patients with atrial fibrillation and atrial flutter in the United States from 2007 to 20192025
  3. 3Predictors for non-persistence to edoxaban in Asian patients with atrial fibrillation: 2-year follow-up data from the ETNA-AF programme2026
  4. 4Direct oral anticoagulation management to address primary and secondary adherence in atrial fibrillation2025
  5. 5Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity2025